Pfizer Launches Plan to Save $4 Billion a Year
Faced with looming generic competition on many of its key products, as well as continuing uncertainty over its arthritis pain drugs, Pfizer has initiated a plan to trim annual costs by $4 billion within three years through such measures as plant closings, administrative cutbacks and sales force streamlining.
The annual cost savings of $4 billion by 2008 represents a 12 percent reduction in Pfizer's current cost base, company executives said during a presentation to analysts. Implementing the plan will cost Pfizer between $5 billion and $6 billion through 2008, the company said.
The financial impact of the cost-savings initiative will be modest in 2005 -- a year Pfizer describes as a "transition year" that will see flat revenues at the firm. Pfizer, however, expects double-digit earnings growth returning in 2006. The savings are expected to yield significant benefits in 2006 and 2007, Pfizer said. Savings will come from a number of areas, noted Hank McKinnell, Pfizer's chairman and CEO. These include streamlining procurement processes, eliminating duplication throughout the firm, improving and standardizing operations systemwide, and closing several manufacturing facilities.
Upcoming Events
-
21Oct